作者
Sabrina Sidali,Raphaël Borie,Flore Sicre de Fontbrune,Kinan El Husseini,Pierre‐Emmanuel Rautou,Élodie Lainey,Odile Goria,Bruno Crestani,Jacques Cadranel,Vincent Cottin,Vincent Bunel,Jérôme Dumortier,Emmanuel Jacquemin,Noémi Reboux,Sandrine Hirschi,Arnaud Bourdin,Magdalena Meszaros,Sébastien Dharancy,Sophie Hilaire,Vincent Mallet,Martine Reynaud‐Gaubert,Louis Terriou,F. Gottrand,Wadih Abou Chahla,Jean-Emmanuel Khan,Paul Carrier,Faouzi Saliba,Laura Rubbia‐Brandt,John‐David Aubert,Laure Elkrief,Victor de Lédinghen,Armand Abergel,Olivier Tournilhac,Pauline Houssel,S. Jouneau,L Wemeau,Anne Bergeron,Thierry Leblanc,Isabelle Ollivier‐Hourmand,Eric Nguyen Khac,Hélène Morisse‐Pradier,Ibrahima Ba,Cathérine Boileau,Françoise Roudot‐Thoraval,Valérie Vilgrain,Christophe Bureau,Hilario Nunès,Jean‐Marc Naccache,François Durand,Claire Francoz,Dominique Roulot,Dominique Valla,Valérie Paradis,Caroline Kannengiesser,Aurélie Plessier
摘要
Background and Aim: Germline mutations of telomere-related genes (TRG) induce multiorgan dysfunction, and liver-specific manifestations have not been clearly outlined. We aimed to describe TRG mutations-associated liver diseases. Approach and Results: Retrospective multicenter analysis of liver disease (transaminases > 30 IU/L and/or abnormal liver imaging) in patients with TRG mutations. Main measurements were characteristics, outcomes, and risk factors of liver disease in a TRG mutations cohort. The prevalence of liver disease was compared to a community-based control group (n = 1190) stratified for age and matched 1:3 for known risk factors of liver disease. Among 132 patients with TRG mutations, 95 (72%) had liver disease, with associated lung, blood, skin, rheumatological, and ophthalmological TRG diseases in 82%, 77%, 55%, 39%, and 30% of cases, respectively. Liver biopsy was performed in 52/95 patients, identifying porto-sinusoidal vascular disease in 48% and advanced fibrosis/cirrhosis in 15%. After a follow-up of 21 months (12–54), ascites, hepato-pulmonary syndrome, variceal bleeding, and HCC occurred in 14%, 13%, 13%, and 2% of cases, respectively. Five-year liver transplantation-free survival was 69%. A FIB-4 score ≥ 3·25 and ≥1 risk factor for cirrhosis were associated with poor liver transplantation-free survival. Liver disease was more frequent in patients with TRG mutations than in the paired control group [80/396, (20%)], OR 12.9 (CI 95%: 7.8–21.3, p < 0.001). Conclusions: TRG mutations significantly increase the risk of developing liver disease. Although symptoms may be mild, they may be associated with severe disease. Porto-sinusoidal vascular disease and cirrhosis were the most frequent lesions, suggesting that the mechanism of action is multifactorial.